Results 91 to 100 of about 993 (163)

Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi

Advanced Science, Volume 12, Issue 37, October 6, 2025.
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda, Kaila Petronila Medina‐Alarcón, João Paulo Soler Gonçalves Pereira, Thais Cristina dos Anjos Sevilhano, Brigitte Aguilar‐Morón, Fernando Díaz‐Cárdenas, Lucas Silva da Cruz, Francisco Humberto Xavier‐Júnior, Eduardo Festozo Vicente, João Perdigão, Beatriz G. de la Torre, Fernando Albericio, Fernando Rogério Pavan   +12 more
wiley   +1 more source

Aspiring Antifungals: Review of Current Antifungal Pipeline Developments

Journal of Fungi, 2020
Invasive fungal infections are associated with significant morbidity and mortality, and their management is restricted to a variety of agents from five established classes of antifungal medication.
Thomas J. Gintjee, Monica A. Donnelley, George R. Thompson   +2 more
doaj   +1 more source

Synthesis and Biological Evaluation of Novel 2‐(Piperidin‐4‐yl)‐1,2,3,4‐tetrahydroisoquinoline and 2‐(Piperidin‐4‐yl)decahydroisoquinoline Antimycotics

Archiv der Pharmazie, Volume 358, Issue 10, October 2025.
A series of 13 hybrid molecules of both lead structures were prepared using reductive amination as key reaction step. The antimycotic potency of the resulting compounds was evaluated against yeast and mold species. Two compounds showed remarkable potency against several yeasts, and even against Candida krusei.
Marie‐Christin Hain, Monika Klimt, Franz Bracher, Ulrike Binder, Jürgen Krauß   +4 more
wiley   +1 more source

Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. [PDF]

Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was non-inferior to caspofungin for Day 30 all-cause mortality (ACM) and Day 14 global cure in the Phase 3 ReSTORE trial (NCT03667690).
Kim, Young Keun, Pullman, John, Haihui, Huang, Sandison, Taylor, Kim, Young, Thompson, George, Kullberg, Bart Jan, Bassetti, Matteo, Cornely, Oliver A, Manamley, Nick, Soriano, Alex, Kullberg, Bart, Honoré, Patrick, Chayakulkeeree, Methee, Cornely, Oliver, Dupont, Hervé, Kollef, Marin, Dignani, Cecilia, Vazquez, Jose A, Thompson Iii, George R, Vazquez, Jose, Pappas, Peter   +21 more
core   +3 more sources

Successful treatment with rezafungin after micafungin for relapsing Rasamsonia argillacea species complex pneumonia in a patient with bronchiectasis: A case report

International Journal of Infectious Diseases
Rasamsonia argillacea species complex are emerging opportunistic molds increasingly reported in patients with chronic lung disease. We describe a 69-year-old woman with bronchiectasis who developed relapsing R. aegroticola pneumonia.
Hugo Bes-Berlandier, Noémie Coron, Heloise Pottier, Sabrina Manni, Coline Mortier, Jean Philippe Bouchara, Coralie Barrera, Anne-Pauline Bellanger-Clerget, Laurence Millon, Perrine Parize, Fanny Lanternier, Olivier Lortholary, Julien Bermudez, Nadim Cassir, Benjamin Coiffard   +14 more
doaj   +1 more source

A rezafungin, mint új generációs echinocandin bemutatása és lehetséges szerepe az antifungális terápiában

, 2019
Napjainkban a leggyakoribb szisztémás gombafertőzés az invazív candidiázis, amit a különböző Candida fajok okoznak. A betegség mortalitása meghaladja a 40%-ot.
Kiss, Csaba
core  

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

, 2018
Rezafungin (CD101) is a novel echinocandin antifungal agent with activity against Aspergillus and Candida species, including azole- and echinocandin-resistant isolates.
Shawn Flanagan, Voon Ong, Paul G. Ambrose, Taylor Sandison, Christopher M. Rubino, Sujata M. Bhavnani, Elizabeth A. Lakota, Justin C. Bader   +7 more
core   +1 more source

Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method

, 2020
Rezafungin (formerly CD101) is a novel echinocandin in clinical development. EUCAST epidemiological cutoff values (ECOFFs) have not yet been established.
Helleberg, Marie, Hare, Rasmus Krøger, Datcu, Raluca, Chowdhary, Anuradha, Arendrup, Maiken Cavling, Jørgensen, Karin Meinike   +5 more
core   +1 more source

The In Vitro Activity of Rezafungin Against Uncommon Species of Candida

Mycoses
ABSTRACTBackgroundInvasive candidiasis (IC) is increasing due to the rising numbers of immunocompromised patients. Increasing azole resistance rates and daily dosing required for most echinocandins have complicated its treatment. The approval of rezafungin has provided an option for weekly echinocandin treatment.
Marisa L. Winkler, Paul Rhomberg, Abigail L. Klauer, Samuel Edeker, Mariana Castanheira   +4 more
openaire   +2 more sources

Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024

Clinical and Translational Science, Volume 18, Issue 7, July 2025.
ABSTRACT The risk of clinically relevant drug–drug interactions (DDIs) for therapeutic peptides remains unclear, mandating a comprehensive analysis for this modality. In our prior study, we analyzed DDIs for 31 peptide drugs approved between January 2008 and August 2021.
Carolina Säll, Upendra Argikar, Constanze Hilgendorf, Hilmar Schiller, Anders Sonesson, Kenichi Umehara, Kai Wang   +6 more
wiley   +1 more source